Crohn’s Disease | Disease Landscape and Forecast | G7 | 2018


The Crohn’s disease(CD) therapy market will continue to evolve over the next decade. The well-established TNF-α inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s Humira) helped transform the treatment landscape, especially for patients with moderate to severe disease, despite these agent’s limitations in efficacy (e.g., patients lose response over time) and safety risks. Takeda’s Entyvio, a cell adhesion molecule (CAM) inhibitor, and the introduction of the first-in-class interleukin (IL)-12/23 inhibitor, Janssen’s Stelara, have expanded physicians’ treatment armamentarium, especially for patients refractory to TNF-α inhibitors. Emerging therapies, which offer more-convenient formulations and/or havenovel mechanisms of action (e.g., Galapagos/Gilead’s filgotinib, TiGenix/Takeda’s Alofisel, AbbVie’s risankizumab), together with the increasing availability of biosimilar agents, will only intensify the competition.


  • What are key opinion leaders’ (KOLs’) insights on current treatment options (e.g., Remicade, Humira)? What is their perception of biosimilar agents? What factors drive their treatment decisions?
  • How have/will the newer, non-TNF biologics (e.g., Janssen’s Stelara, Takeda’s Entyvio, Roche’s etrolizumab) affect the CD treatment algorithm?
  • What do KOLs think about emerging oral therapies (e.g., Galapagos/Gilead’s filgotinib, AbbVie’s upadacitinib)? What impact will stem-cell therapy (i.e., TiGenix/Takeda’s Alofisel) have on the CD market?
  • How will the market evolve over the next ten years? What are KOLs’ insights on current treatment options for CD (e.g., Remicade, Humira, Inflectra/Remsima)? What factors drive their treatment decisions?


Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Login to access report